Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Payment, Tax Withholding, Share-Based Payment Arrangement

Payment, Tax Withholding, Share-Based Payment Arrangement at other companies

UFP Technologies logo
UFP TechnologiesUFPT
$3.57M-8.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——
Trimas logo
TrimasTRS
——
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
——

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$23.72B+30.4%
Enterprise value$23.6B+31.2%
P/E42×+4.7×
P/S7.1×+1.0×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement?
West Pharmaceutical Services (WST) reported payment, tax withholding, share-based payment arrangement of $2.5M in Q1 2026.
How has West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement changed year-over-year?
West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement decreased by 0.0% year-over-year, from $2.5M to $2.5M.
What is the long-term trend for West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement?
Over 4 years (2021 to 2025), West Pharmaceutical Services's payment, tax withholding, share-based payment arrangement has grown at a -34.0% compound annual growth rate (CAGR), from $14.8M to $2.8M.